You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Phosphodiesterase-5 inhibitors as novel cardioprotective agents: have we reached threshold for large-scale clinical trials?
  1. David Charles Hutchings,
  2. Simon George Anderson,
  3. Andrew W Trafford
  1. Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK
  1. Correspondence to Dr. David Charles Hutchings, Institute of Cardiovascular Sciences, University of Manchester, 46 Grafton Street, Manchester M139NT, UK; hutchingsdc{at}googlemail.com

https://doi.org/10.1136/heartjnl-2017-311788

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    To the Editor

    We read with great interest the compelling findings of Andersson et al demonstrating strong association between on-demand use of phosphodiesterase-5 (PDE5) inhibitors (PDE5is) and a reduction in cardiovascular mortality and heart failure hospitalisation in patients followed up following their first myocardial infarction (MI). We previously reported in Heart a similarly strong association between PDE5i use and reduced mortality in a cohort of patients with type 2 diabetes and attendant high cardiovascular risk.1 In our study, we showed that the association was stronger in patients with prior MI, supporting a cardioprotective action, although we were unable to …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.